




# MEDICINAL PRODUCTS 2022

Chemours Co  
Rank 31 of 51





# MEDICINAL PRODUCTS 2022

Chemours Co  
Rank 31 of 51



The relative strengths and weaknesses of Chemours Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemours Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Chemours Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 21%, being 35% points above the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	3,345,000
Assets, Non-Current	843,000
General and Administrative Expense	5,556,000
Goodwill	102,000
Liabilities, Current	1,907,000
Liabilities, Non-Current	4,561,000
Other Assets	106,000
Other Compr. Net Income	-54,000
Other Expenses	259,000
Other Liabilities	0
Other Net Income	185,000
Other Revenues	6,345,000
Property, Plant and Equipment, Net	3,154,000
Research and Development	107,000

Output Variable	Value in 1000 USD
Liabilities	6,468,000
Assets	7,550,000
Expenses	5,922,000
Revenues	6,345,000
Stockholders Equity	1,082,000
Net Income	608,000
Comprehensive Net Income	581,000
Economic Capital Ratio	21%